Protalix Biotherapeutics Stock Market Value
| PLX Stock | USD 2.06 0.06 2.83% |
| Symbol | Protalix |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. Anticipated expansion of Protalix directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Protalix Biotherapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.01) | Earnings Share 0.08 | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Protalix Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Protalix Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Protalix Biotherapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Protalix Biotherapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Protalix Biotherapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Protalix Biotherapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Protalix Biotherapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Protalix Biotherapeutics or generate 0.0% return on investment in Protalix Biotherapeutics over 90 days. Protalix Biotherapeutics is related to or competes with Sellas Life, Coherus BioSciences, Invivyd, Protara Therapeutics, Codexis, OmniAb, and NeOnc Technologies. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombi... More
Protalix Biotherapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Protalix Biotherapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Protalix Biotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 16.17 | |||
| Value At Risk | (4.64) | |||
| Potential Upside | 3.5 |
Protalix Biotherapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protalix Biotherapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Protalix Biotherapeutics' standard deviation. In reality, there are many statistical measures that can use Protalix Biotherapeutics historical prices to predict the future Protalix Biotherapeutics' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.09) |
Protalix Biotherapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.08) | |||
| Mean Deviation | 2.43 | |||
| Coefficient Of Variation | (2,640) | |||
| Standard Deviation | 3.23 | |||
| Variance | 10.41 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.09) | |||
| Maximum Drawdown | 16.17 | |||
| Value At Risk | (4.64) | |||
| Potential Upside | 3.5 | |||
| Skewness | 0.2862 | |||
| Kurtosis | 3.09 |
Protalix Biotherapeutics Backtested Returns
Protalix Biotherapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.0572, which implies the firm had a -0.0572 % return per unit of risk over the last 3 months. Protalix Biotherapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Protalix Biotherapeutics' Variance of 10.41, coefficient of variation of (2,640), and Risk Adjusted Performance of (0.02) to confirm the risk estimate we provide. The company holds a Beta of 1.42, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Protalix Biotherapeutics will likely underperform. At this point, Protalix Biotherapeutics has a negative expected return of -0.18%. Please make sure to check Protalix Biotherapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Protalix Biotherapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.65 |
Very good reverse predictability
Protalix Biotherapeutics has very good reverse predictability. Overlapping area represents the amount of predictability between Protalix Biotherapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Protalix Biotherapeutics price movement. The serial correlation of -0.65 indicates that roughly 65.0% of current Protalix Biotherapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.65 | |
| Spearman Rank Test | -0.75 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.